• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by GH Research PLC (Amendment)

    2/10/23 4:35:16 PM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GHRS alert in real time by email
    SC 13G/A 1 dp188707_sc13ga1-florian.htm FORM SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G/A

    (Rule 13d-102) 

     

    Information Statement Pursuant to Rules 13d-1 and 13d-2

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

     

     

    GH RESEARCH PLC

    (Name of Issuer)

     

    Ordinary shares, nominal value $0.025 per share

    (Title of Class of Securities)

     

    G3855L106

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☐Rule 13d-1(c)

     

    ☒Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

             
    CUSIP No. G3855L106   13G/A   Page 2 of 6 Pages
                 
    1  

    NAME OF REPORTING PERSON

     

    Florian Schonharting

     

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

    (a) ☐ (b) ☐

     

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Denmark

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      5  

    SOLE VOTING POWER

     

    14,824,419 Ordinary Shares

     

      6  

    SHARED VOTING POWER

     

    0

     

      7  

    SOLE DISPOSITIVE POWER

     

    14,824,419 Ordinary Shares

     

      8  

    SHARED DISPOSITIVE POWER

     

    0

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,824,419 Ordinary Shares

     

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    28.5% (1)

     

    12  

    TYPE OF REPORTING PERSON

     

    IN

     

     

    (1) This percentage is calculated based on 52,020,849 ordinary shares outstanding as of December 31, 2022. 

     

     

     

             
    CUSIP No. G3855L106   13G/A   Page 3 of 6 Pages

     

    Item 1(a). Name of Issuer 

     

    The name of the issuer to which this filing on Schedule 13G/A relates is GH Research PLC (the “Company”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices 

     

    The principal executive offices of the Company are located at 28 Baggot Street Lower, Dublin 2, D02 NX43, Ireland.

     

    Item 2(a).

    Name of Person Filing

     

    Florian Schonharting.

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence 

     

    Ostergade 24A, 1st Floor, DK-1100, Copenhagen, Denmark.

     

    Item 2(c). Citizenship 

     

    Denmark.

     

    Item 2(d). Title of Class of Securities 

     

    The class of equity securities of the Company to which this filing on Schedule 13G/A relates is ordinary shares, nominal value $0.025 per share (the “Ordinary Shares”).

     

    Item 2(e). CUSIP Number 

     

    The CUSIP number of the Company’s Ordinary Shares is G3855L106.

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: 

     

    Not applicable.

     

     

     

     

    CUSIP No. G3855L106   13G/A   Page 4 of 6 Pages

     

    Item 4. Ownership 

     

    Item 4(a). Amount beneficially owned 

     

    14,824,419 Ordinary Shares.

     

    Item4 (b).Percent of Class

     

    28.5%. The calculation of the percentage of Ordinary Shares beneficially owned assumes 52,020,849 Ordinary Shares outstanding as of December 31, 2022.

     

    Item 4 (c).Number of shares as to which such person has:

     

      (i) sole power to vote or to direct the vote: 14,824,419

     

      (ii) shared power to vote or to direct the vote: 0

     

      (iii) sole power to dispose or to direct the disposition of: 14,824,419

     

      (iv) shared power to dispose or to direct the disposition of: 0

     

    Item 5. Ownership of Five Percent or Less of a Class 

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person 

     

    Not applicable.

     

     

     

             
    CUSIP No. G3855L106   13G/A   Page 5 of 6 Pages

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group 

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group 

     

    Not applicable.

     

    Item 10. Certification 

     

    The Reporting Person hereby makes the following certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

     

    Dated: February 10, 2023

     

         
     

    Florian Schonharting

     

         
      By: /s/ Florian Schonharting
      Name: Florian Schonharting

     

     

     

    Get the next $GHRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GHRS

    DatePrice TargetRatingAnalyst
    10/13/2025$19.00Buy
    Needham
    6/4/2025$25.00Overweight
    Cantor Fitzgerald
    3/13/2025$32.00Buy
    Guggenheim
    3/7/2025$31.00Outperform
    RBC Capital Mkts
    2/13/2025$14.00Overweight
    Cantor Fitzgerald
    8/16/2022$45.00Buy
    H.C. Wainwright
    6/16/2022$66.00Buy
    ROTH Capital
    7/20/2021Buy
    Stifel
    More analyst ratings

    $GHRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on GH Research PLC with a new price target

    Needham initiated coverage of GH Research PLC with a rating of Buy and set a new price target of $19.00

    10/13/25 8:53:27 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on GH Research PLC with a new price target

    Cantor Fitzgerald resumed coverage of GH Research PLC with a rating of Overweight and set a new price target of $25.00

    6/4/25 8:19:53 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on GH Research PLC with a new price target

    Guggenheim initiated coverage of GH Research PLC with a rating of Buy and set a new price target of $32.00

    3/13/25 7:38:21 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GHRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026

    GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program replicating Phase 2b designPhase 3 initiation targeted for 2026 DUBLIN, Jan. 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug Application (IND) for GH001. This clearance enables U.S. subject enrollment and progresses the company toward alignment of its development ac

    1/5/26 7:00:00 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GH Research to Announce IND Status for GH001

    DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported that it will provide an update on the status of its Investigational New Drug Application (IND) for GH001 with the U.S. Food and Drug Administration (FDA) and its global pivotal Phase 3 program in treatment-resistant depression (TRD) on Monday, January 5, 2026, at 7.00 a.m. EST. About GH Research PLC GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in

    1/2/26 4:01:00 PM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress

    DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Novel Therapies Symposium Presentation at the 38th Annual European College of Neuropsychopharmacology Congress (ECNP) in Amsterdam, the Netherlands from October 11 – 14, where Professor Wiesław J. Cubała, MD, PhD, Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, will present long-term clinical data on the safety and efficacy from the open label extension (OLE) of a randomized, double-blind, placebo-controlle

    10/9/25 7:00:07 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GHRS
    SEC Filings

    View All

    SEC Form 6-K filed by GH Research PLC

    6-K - GH Research PLC (0001855129) (Filer)

    1/22/26 7:02:30 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by GH Research PLC

    6-K - GH Research PLC (0001855129) (Filer)

    1/15/26 7:00:51 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by GH Research PLC

    6-K - GH Research PLC (0001855129) (Filer)

    1/13/26 7:15:47 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GHRS
    Financials

    Live finance-specific insights

    View All

    GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

    Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients treated with GH001 achieved remission with a 57.5% remission rate on Day 8 compared with 0% in the placebo group (p<0.0001)All other secondary endpoints were met with clinically and statistically significant improvements on Day 8, compared with placeboDuring the double-blind part, GH001 was well tolerated and no serious adverse events (SAE) were reported. There was no evidence of treatment-emergent suicidal ideation or behavior. As of January 22, 2025, no SAEs have been reported throughout the open

    2/3/25 7:00:10 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

    DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD). To access the conference call, please register in advance here. A live webcast of the call will be available under "Events & Presentations" in the Investors section of GH Research PLC's website at ghres.com. About GH Research PLC GH

    1/31/25 4:01:35 PM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GHRS
    Leadership Updates

    Live Leadership Updates

    View All

    GH Research Announces Appointment of Dr. Velichka "Villy" Valcheva to Chief Executive Officer

    DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the promotion of Dr. Velichka "Villy" Valcheva, MD, MSc. to Chief Executive Officer of the Company. Dr. Valcheva succeeds PD Dr. med. Theis Terwey, co-founder of GH Research. Dr. Valcheva has more than 20 years of experience in various leadership roles in the pharmaceutical and biotech industries. Dr. Valcheva joined the company in August 2023 and has served as the Company's Chief Medical Officer since February 2024 having leadership responsibility, among other thin

    9/3/24 7:00:05 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

    DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates. Second Quarter 2023 Financial Highlights Cash position Cash, cash equivalents, other financial assets and marketable securities were $238.1 million as of June 30, 2023, compared to cash, cash equivalents and marketable securities of $251.7 million as of December 31, 2022. Cash equivalents and other financial assets comprise money market funds. Marketable securities comprise inv

    8/23/23 7:00:45 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GHRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GH Research PLC

    SC 13G/A - GH Research PLC (0001855129) (Subject)

    11/14/24 5:46:11 PM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by GH Research PLC

    SC 13G/A - GH Research PLC (0001855129) (Subject)

    11/14/24 9:05:43 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by GH Research PLC

    SC 13G - GH Research PLC (0001855129) (Subject)

    2/16/24 4:57:41 PM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care